Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health (PE)
Primary Purpose
Obesity, Insulin Resistance
Status
Completed
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Weight loss with very low fat plant-based diet and regular exercise
Sponsored by
About this trial
This is an interventional other trial for Obesity
Eligibility Criteria
Inclusion Criteria:
- Age ≥18 and ≤55 years
- BMI ≥30.0 and ≤50.0 kg/m²
- IHTG content ≥5.6%; HbA1c ≥5.7%, or fasting plasma glucose concentration ≥100 mg/dl, or 2-hr OGTT plasma glucose concentration ≥140 mg/dl OR HbA1c ≥5.8% and 2-hr OGTT plasma glucose concentration ≥150 mg/dl
Exclusion Criteria:
- Medical, surgical, or biological menopause
- Previous bariatric surgery
- Structured exercise >2 days/week for ≥35 minutes of intense exercise (e.g., jogging, activity that causes heavy breathing and sweating) or ≥150 min per week of structured exercise (e.g., brisk walking)
- Unstable weight (>4% change during the last 2 months before entering the study)
- Significant organ system dysfunction (e.g., diabetes requiring medications, severe pulmonary, kidney or cardiovascular disease)
- Cancer or cancer that has been in remission for <5 years
- Polycystic ovary syndrome
- Major psychiatric illness
- Conditions that render subject unable to complete all testing procedures (e.g., severe ambulatory impairments, limb amputations, or metal implants that interfere with imaging procedures; coagulation disorders)
- Use of medications that are known to affect the study outcome measures (e.g., steroids, non-statin lipid lowering medications) or increase the risk of study procedures (e.g., anticoagulants) and that cannot be temporarily discontinued for this study
- Use of antibiotics in last 60 days
- Smoke cigarettes, use marijuana >2 x/week, or use of illegal drugs
- Men who consume >21 units (e.g. glass of wine or bottle of beer) of alcohol per week and women who consume >14 units of alcohol per week
- Pregnant or lactating women
- Vegans
- Persons who are not able to grant voluntary informed consent
- Persons who are unable or unwilling to follow the study protocol or who, for any reason, the research team considers not an appropriate candidate for this study, including non-compliance with screening appointments or study visits
Sites / Locations
- Washington University in St. Louis School of Medicine
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
Weight loss with diet with exercise
Arm Description
Persons with obesity with blood glucose concentrations higher than recommended and a moderate to high amount of fat in the liver (people with metabolically abnormal obesity) will be tested before and after ~7-10% weight loss. Following baseline testing, participants will be placed on a caloric-restricted plant-based very-low-fat (PB) diet and an exercise program until ~7-10% weight loss is achieved; they will then be re-tested so that pre- and post-intervention outcomes can be compared.
Outcomes
Primary Outcome Measures
Change in insulin sensitivity
Liver and skeletal muscle insulin sensitivity will be assessed by hyperinsulinemic euglycemic clamp technique, before and after weight loss.
Secondary Outcome Measures
Change in aerobic fitness
Maximal oxygen consumption will be assessed using indirect calorimetry during a graded exercise test to volitional fatigue, before and after weight loss.
Change in muscular strength
Muscle strength will be evaluated as the maximal amount of weight the participant is able to lift for one repetition (1 RM) for the following exercises: leg press, seated row, knee flexion, and chest press, before and after weight loss.
Change in fat mass and fat free mass
Fat mass and fat free mass will be assessed using dual-energy x-ray absorptiometry (DXA) before and after weight loss.
Change in intra-hepatic triglyceride content
Intra-hepatic triglyceride content will be assessed by magnetic resonance imaging (MRI) before and after weight loss.
Change in fasting plasma glucose
Fasting plasma glucose concentrations will be evaluated from a fasting blood sample before and after weight loss.
Change in glycosylated hemoglobin (HbA1c)
HbA1c will be evaluated from a fasting blood sample before and after weight loss.
Change in 24 hour glucose concentrations with feeding
Glucose concentrations will be evaluated from frequent blood samples over a 24 h period, before and after weight loss, with the participant consuming mixed meals throughout the day.
Change in 24 hour metabolite concentrations with feeding
Metabolite concentrations will be evaluated from frequent blood samples over a 24 h period, before and after weight loss, with the participant consuming mixed meals throughout the day.
Change in 24 hour hormone concentrations with feeding
Hormone concentrations will be evaluated from frequent blood samples over a 24 h period, before and after weight loss, with the participant consuming mixed meals throughout the day.
Change in markers of inflammation
Markers of inflammation will be evaluated from blood samples collected before and after weight loss.
Change in plasma proteome
Plasma proteome will be evaluated from blood samples collected before and after weight loss.
Changes in gene expression in skeletal muscle tissue
Gene expression in thigh muscle tissue will be evaluated before and after weight loss.
Changes in body weight
Body weight will be measured before and after weight loss.
Changes in body mass index
Body mass index will be calculated from weight and height before and after weight loss.
Change in exosome-mediated intercellular signaling
Signaling between cells and organs will be examined by isolating exosomes (small extracellular vesicles) from blood
Change in gut microbiome
Gut microbiota, meta-transcriptome (bacterial RNA sequencing to determine what proteins can be made by the microbiota) and the meta-metabolome (metabolites made by the microbiota) will be assessed before and after weight loss.
Change in beta-cell function
Beta-cell function will be assessed from a modified oral glucose tolerance test before and after weight loss.
Change in insulin clearance
Beta-cell function will be assessed from a modified oral glucose tolerance test and during the 24-hour study performed before and after weight loss.
Full Information
NCT ID
NCT02706288
First Posted
February 16, 2016
Last Updated
December 5, 2022
Sponsor
Washington University School of Medicine
Collaborators
The Foundation for Barnes-Jewish Hospital
1. Study Identification
Unique Protocol Identification Number
NCT02706288
Brief Title
Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health
Acronym
PE
Official Title
The Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health in Metabolically Abnormal Obese Adults
Study Type
Interventional
2. Study Status
Record Verification Date
December 2022
Overall Recruitment Status
Completed
Study Start Date
March 2016 (Actual)
Primary Completion Date
December 2020 (Actual)
Study Completion Date
December 2022 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Washington University School of Medicine
Collaborators
The Foundation for Barnes-Jewish Hospital
4. Oversight
Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to understand how weight loss by a very low fat plant-based diet with an exercise program affects metabolic and cardiovascular health in overweight adults at high risk for disease. Outcome measures will include assessment of insulin sensitivity, β-cell function, body fat distribution, skeletal muscle and adipose tissue biology, cardiovascular function, cardiorespiratory fitness, muscular strength, immune function, and the gut microbiome.
Detailed Description
Reduced energy intake and increased physical activity have profound effects on cardiometabolic health as assessed by insulin sensitivity, β-cell function, serum lipids, intra-abdominal fat mass, intrahepatic triglyceride content, and blood pressure, and is the cornerstone of treatment for people with obesity. However, the specific additional therapeutic effects of regular exercise in conjunction with diet-induced weight loss are not clear. In addition, the optimal dietary macronutrient composition needed to reduce cardiometabolic risk is not known. The use of a very low fat, plant-forward diet is becoming increasingly popular to treat people with obesity and is the only diet therapy that is reimbursed by Medicare in the treatment of people with coronary heart disease.
Participants will undergo nutritional counseling and have supervised exercise training 4 days per week plus unsupervised exercise sessions performed 2 days per week until 7-10% weight loss is achieved. Meals will be provided and food diaries will be kept during weight loss. Tests before and after the intervention will include muscular strength and aerobic fitness, cardiovascular assessments, glucose tolerance tests, hyperinsulinemic euglycemic clamp test for insulin sensitivity, muscle biopsies, body composition scans, blood tests, and urine and stool collections.
The overarching goal of this project is to conduct a comprehensive characterization of weight loss induced by using a PB diet with regular exercise in people with obesity, prediabetes and insulin resistance, followed by a comparison of the effects of this study with those from another study that is evaluating the effect of the same amount of weight loss induced by using a PB diet alone, without exercise. Specifically, we will evaluate changes in body composition, body fat distribution, cardiopulmonary function, muscle strength, the plasma proteome, insulin sensitivity, beta-cell function, systemic inflammation, muscle cellular metabolic pathways, and the gut microbiome to determine cellular, multiorgan, and whole-body effects of PB diet alone and PB diet plus exercise. Accordingly, this study will fill two important gaps in our knowledge that have considerable physiological and clinical significance; the data from this study will provide: 1) a better understanding of the effects of calorie restriction-induced weight loss plus exercise on a series of key outcome measures, and 2) the potential additional benefit of adding regular exercise to a plant-forward diet.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Insulin Resistance
7. Study Design
Primary Purpose
Other
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
8 (Actual)
8. Arms, Groups, and Interventions
Arm Title
Weight loss with diet with exercise
Arm Type
Experimental
Arm Description
Persons with obesity with blood glucose concentrations higher than recommended and a moderate to high amount of fat in the liver (people with metabolically abnormal obesity) will be tested before and after ~7-10% weight loss. Following baseline testing, participants will be placed on a caloric-restricted plant-based very-low-fat (PB) diet and an exercise program until ~7-10% weight loss is achieved; they will then be re-tested so that pre- and post-intervention outcomes can be compared.
Intervention Type
Other
Intervention Name(s)
Weight loss with very low fat plant-based diet and regular exercise
Intervention Description
Participants will lose ~7-10% of their body weight while on a calorie-restricted very low fat plant-based (PB) diet and performing exercise 6 days/week (4 sessions/week under direct supervision). The macronutrient composition of the diet is approximately 70% of energy from carbohydrate, 15% from protein, and 15% from fat. Food will be provided in the form of take-out meals and will be picked up by participants during weekly study visits with a weight management dietitian. To promote adherence to the diet and exercise intervention, subjects will participate in a lifestyle intervention program that includes dietary and behavioral education topics. Treatment will be provided in weekly individual or group sessions depending on subject availability. (Note: this is the only intervention for the study; the hyperinsulinemic euglycemic clamp is not an intervention but is the gold standard for evaluating insulin sensitivity, a primary study outcome.)
Primary Outcome Measure Information:
Title
Change in insulin sensitivity
Description
Liver and skeletal muscle insulin sensitivity will be assessed by hyperinsulinemic euglycemic clamp technique, before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Secondary Outcome Measure Information:
Title
Change in aerobic fitness
Description
Maximal oxygen consumption will be assessed using indirect calorimetry during a graded exercise test to volitional fatigue, before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in muscular strength
Description
Muscle strength will be evaluated as the maximal amount of weight the participant is able to lift for one repetition (1 RM) for the following exercises: leg press, seated row, knee flexion, and chest press, before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in fat mass and fat free mass
Description
Fat mass and fat free mass will be assessed using dual-energy x-ray absorptiometry (DXA) before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in intra-hepatic triglyceride content
Description
Intra-hepatic triglyceride content will be assessed by magnetic resonance imaging (MRI) before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in fasting plasma glucose
Description
Fasting plasma glucose concentrations will be evaluated from a fasting blood sample before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in glycosylated hemoglobin (HbA1c)
Description
HbA1c will be evaluated from a fasting blood sample before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in 24 hour glucose concentrations with feeding
Description
Glucose concentrations will be evaluated from frequent blood samples over a 24 h period, before and after weight loss, with the participant consuming mixed meals throughout the day.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in 24 hour metabolite concentrations with feeding
Description
Metabolite concentrations will be evaluated from frequent blood samples over a 24 h period, before and after weight loss, with the participant consuming mixed meals throughout the day.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in 24 hour hormone concentrations with feeding
Description
Hormone concentrations will be evaluated from frequent blood samples over a 24 h period, before and after weight loss, with the participant consuming mixed meals throughout the day.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in markers of inflammation
Description
Markers of inflammation will be evaluated from blood samples collected before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in plasma proteome
Description
Plasma proteome will be evaluated from blood samples collected before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Changes in gene expression in skeletal muscle tissue
Description
Gene expression in thigh muscle tissue will be evaluated before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Changes in body weight
Description
Body weight will be measured before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Changes in body mass index
Description
Body mass index will be calculated from weight and height before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in exosome-mediated intercellular signaling
Description
Signaling between cells and organs will be examined by isolating exosomes (small extracellular vesicles) from blood
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in gut microbiome
Description
Gut microbiota, meta-transcriptome (bacterial RNA sequencing to determine what proteins can be made by the microbiota) and the meta-metabolome (metabolites made by the microbiota) will be assessed before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in beta-cell function
Description
Beta-cell function will be assessed from a modified oral glucose tolerance test before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
Title
Change in insulin clearance
Description
Beta-cell function will be assessed from a modified oral glucose tolerance test and during the 24-hour study performed before and after weight loss.
Time Frame
An average of 4 months from baseline testing to 7-10% weight loss
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
55 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria:
Age ≥18 and ≤55 years
BMI ≥30.0 and ≤50.0 kg/m²
HbA1c ≥5.7%, or fasting plasma glucose concentration ≥100 mg/dl, or 2-hr OGTT plasma glucose concentration ≥140 mg/dl
Exclusion Criteria:
Medical, surgical, or biological menopause
Previous bariatric surgery
Structured exercise >2 days/week for ≥35 minutes of intense exercise (e.g., jogging, activity that causes heavy breathing and sweating) or ≥150 min per week of structured exercise (e.g., brisk walking)
Unstable weight (>4% change during the last 2 months before entering the study)
Significant organ system dysfunction (e.g., diabetes requiring medications, severe pulmonary, kidney or cardiovascular disease)
Cancer or cancer that has been in remission for <5 years
Polycystic ovary syndrome
Major psychiatric illness
Conditions that render subject unable to complete all testing procedures (e.g., severe ambulatory impairments, limb amputations, or metal implants that interfere with imaging procedures; coagulation disorders)
Use of medications that are known to affect the study outcome measures (e.g., steroids, non-statin lipid lowering medications) or increase the risk of study procedures (e.g., anticoagulants) and that cannot be temporarily discontinued for this study
Use of antibiotics in last 60 days
Smoke cigarettes, use marijuana >2 x/week, or use of illegal drugs
Men who consume >21 units (e.g. glass of wine or bottle of beer) of alcohol per week and women who consume >14 units of alcohol per week
Pregnant or lactating women
Vegans, vegetarians, those with lactose intolerance and/or severe aversions/sensitivities to eggs, fish, nuts, wheat and soy, and/or any individuals with food allergies that induce an anaphylactic response
Persons who are not able to grant voluntary informed consent
Persons who are unable or unwilling to follow the study protocol or who, for any reason, the research team considers not an appropriate candidate for this study, including non-compliance with screening appointments or study visits
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Samuel Klein, MD
Organizational Affiliation
Washington University School of Medicine
Official's Role
Principal Investigator
Facility Information:
Facility Name
Washington University in St. Louis School of Medicine
City
Saint Louis
State/Province
Missouri
ZIP/Postal Code
63110
Country
United States
12. IPD Sharing Statement
Plan to Share IPD
No
IPD Sharing Plan Description
All of the data from individual subjects will be maintained confidentially and their names and identities will not be disclosed in any published document.
Learn more about this trial
Effects of a Calorie Restricted, Very Low Fat Plant-based Diet and Multi-component Exercise Program on Metabolic Health
We'll reach out to this number within 24 hrs